Browse By Cell Line Result Page of OvirusTdb
The total number of records retrieved from this search are 5. Click on ID to see further detail.
IDOV_4242 | Virus nameMeasles virus | Virus strainrMV-SLAMblind | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationR533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman nonsmall cell lung carcinoma cell line | Cell lineABC-1 | Concentration of cell line5.0E+3 cells per well | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viability after day 1 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26317644 |
IDOV_4243 | Virus nameMeasles virus | Virus strainrMV-SLAMblind | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationR533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman nonsmall cell lung carcinoma cell line | Cell lineABC-1 | Concentration of cell line5.0E+3 cells per well | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result80% cell viability after day 3 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26317644 |
IDOV_4244 | Virus nameMeasles virus | Virus strainrMV-SLAMblind | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationR533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman nonsmall cell lung carcinoma cell line | Cell lineABC-1 | Concentration of cell line5.0E+3 cells per well | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result60% cell viability after day 5 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26317644 |
IDOV_4245 | Virus nameMeasles virus | Virus strainrMV-SLAMblind | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationR533A substitution was introduced into pMV-HL(7+) and then transfected to vero cell line to produce virus particle | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman nonsmall cell lung carcinoma cell line | Cell lineABC-1 | Concentration of cell line5.0E+3 cells per well | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result45% cell viability after day 7 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26317644 |
IDOV_5915 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman lung cancer cell line | Cell lineABC-1 | Concentration of cell lineNA | In-vitro toxicityNA | AssayWST-1 assay | In-vitro virus concentration1 MOI | In-vitro result60% cell killing after 7 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMIDUS10335481 |